Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Cohort study shows improvement during 25 years of RA treatment

Cohort study shows improvement during 25 years of RA treatment

Presented By
Dr Xanthe Matthijssen, Leiden University Medical Center, the Netherlands
Conference
EULAR 2019
Improvements in treatment strategies during the last 25 years have led to lower disease activity, more sustained drug-free remission, and better physical functioning of rheumatoid arthritis (RA) patients [1]. ACPA-positive patients benefited most from these improvements. Broadly speaking, RA consists of two distinct disease subtypes that are characterised by the presence or absence of RA-related auto-antibodies, of which the presence of anti-citrullinated protein antibodies (ACPA) is most specific for RA. Both subtypes have known differences in the severity of the disease course, and ACPA-positive and ACPA-negative RA may differ in their treatment responses. “What we all know, is that RA treatment has improved drastically with earlier treatment and better medication,” said Dr Xanthe Matthijssen (Leiden University Medical Center, the Netherlands). “However, the difference in treatment response between these two subtypes is still unclear and treatment guidel...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on